Diabetes Drug Made For Under $5 Costs Americans $1,000, Drawing Comparisons To Martin Shrikeli While Juicing Profits for A Drug Giant

Wall Street Analysts Think Novo Nordisk (NVO) Is a Good Investment: Is It?

Wall Street Analysts Think Novo Nordisk (NVO) Is a Good Investment: Is It?

Eli Lilly’s Ozempic Competitors Face Risks. Why the Stock Has More Upside.

Novo Nordisk A/S - share repurchase programme

Here's Why Novo Nordisk (NVO) Fell More Than Broader Market

Here's Why Novo Nordisk (NVO) Fell More Than Broader Market

Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus

Is Novo Nordisk the Best Healthcare Stock for You?

Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock

Ozempic Could Sell at a Profit for $57 a Year, Report Says. It’s Priced at $11,600.

Why Novo Nordisk (NVO) is a Top Stock for the Long-Term

Why Novo Nordisk (NVO) is a Top Stock for the Long-Term

Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says

2 Top Biotech Buyout Candidates

Novo Nordisk Under Fire, Post-Ozempic Study

Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs

Altimmune says weight loss drug minimized muscle loss in trial results that may set it apart

Novo Nordisk's $1,000 diabetes drug Ozempic can be made for less than $5 a month, study suggests

Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data